{"name":"Knight Therapeutics","slug":"knight-therapeutics","ticker":"GUD.TO","exchange":"TSX","domain":"knighttx.com","description":"Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy ","hq":"Montreal, Quebec, Canada","founded":0,"employees":"830","ceo":"","sector":"Specialty Pharma / Licensing & Distribution","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":8.61,"stockChange":0.12,"stockChangePercent":1.41,"marketCap":"$617M","metrics":{"revenue":328018980.89239997,"revenueGrowth":37.4,"grossMargin":44.5,"rdSpend":0,"netIncome":-3916509.6677,"cash":83248787.27795,"dividendYield":0,"peRatio":143.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":328018980.89239997,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":328018980.89239997},{"period":"2024-12-31","value":270602103.76919997},{"period":"2023-12-31","value":239187673.32145},{"period":"2022-12-31","value":213945353.10365}],"grossProfit":145925331.3665,"grossProfitHistory":[{"period":"2025-12-31","value":145925331.3665},{"period":"2024-12-31","value":127104367.06275},{"period":"2023-12-31","value":111251029.7346},{"period":"2022-12-31","value":100617276.00155}],"rdSpend":21123207.3332,"rdSpendHistory":[{"period":"2025-12-31","value":21123207.3332},{"period":"2024-12-31","value":16983688.3692},{"period":"2023-12-31","value":12789510.26395},{"period":"2022-12-31","value":10753275.05525}],"sgaSpend":90449218.15195,"operatingIncome":-1712653.0925,"operatingIncomeHistory":[{"period":"2025-12-31","value":-1712653.0925},{"period":"2024-12-31","value":5390848.9043499995},{"period":"2023-12-31","value":4642383.0635},{"period":"2022-12-31","value":-12433132.662999999}],"netIncome":-3916509.6677,"netIncomeHistory":[{"period":"2025-12-31","value":-3916509.6677},{"period":"2024-12-31","value":3157111.9986},{"period":"2023-12-31","value":-12269155.23925},{"period":"2022-12-31","value":-21784947.3366}],"eps":-0.05,"epsHistory":[{"period":"2025-12-31","value":-0.05},{"period":"2024-12-31","value":0.04},{"period":"2023-12-31","value":-0.16},{"period":"2022-12-31","value":-0.26}],"cash":55715155.85895,"cashHistory":[{"period":"2025-12-31","value":55715155.85895},{"period":"2024-12-31","value":58380335.5863},{"period":"2023-12-31","value":42824343.986549996},{"period":"2022-12-31","value":52238834.47545}],"totalAssets":762531459.865,"totalLiabilities":203352411.5294,"totalDebt":56780644.71905,"equity":559179048.3356,"operatingCashflow":50255072.04235,"operatingCashflowHistory":[{"period":"2025-12-31","value":50255072.04235},{"period":"2024-12-31","value":26440448.594},{"period":"2023-12-31","value":26191931.69845},{"period":"2022-12-31","value":32795484.75}],"capex":-24555801.403699998,"capexHistory":[{"period":"2025-12-31","value":-24555801.403699998},{"period":"2024-12-31","value":-22936433.2456},{"period":"2023-12-31","value":-7257276.3809},{"period":"2022-12-31","value":-18814405.2068}],"freeCashflow":25699270.63865,"dividendsPaid":0,"buybacks":-4629264.8696,"employees":830,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":25838469.2517,"ebit":11039688.9554,"ebitda":22029091.50085,"period":"2025-12-31","revenue":97006128.73629999,"epsBasic":null,"netIncome":6452693.8217,"rdExpense":6721616.79665,"epsDiluted":null,"grossProfit":47169381.32165,"operatingIncome":4525776.8955},{"sga":22948093.8624,"ebit":-9646245.2478,"ebitda":-800209.8279,"period":"2025-06-30","revenue":78241281.15089999,"epsBasic":-0.13,"netIncome":-9198769.0781,"rdExpense":4577520.88255,"epsDiluted":-0.13,"grossProfit":32672319.48505,"operatingIncome":-2673925.18995},{"sga":19052719.06265,"ebit":988966.06235,"ebitda":9431252.62555,"period":"2025-03-31","revenue":64188780.329799995,"epsBasic":0.02,"netIncome":1592402.98175,"rdExpense":3487982.0003,"epsDiluted":0.02,"grossProfit":25409941.5843,"operatingIncome":-4035302.2013499998},{"sga":18450739.72035,"ebit":7522555.4131,"ebitda":17703731.4566,"period":"2024-12-31","revenue":70593374.1072,"epsBasic":null,"netIncome":7823545.084249999,"rdExpense":5367527.67075,"epsDiluted":null,"grossProfit":29408075.5696,"operatingIncome":-2157214.108},{"sga":18570989.8311,"ebit":1838733.51165,"ebitda":11596483.4076,"period":"2024-09-30","revenue":67240217.98865,"epsBasic":0,"netIncome":61947.02675,"rdExpense":3755447.39815,"epsDiluted":0,"grossProfit":32807874.15535,"operatingIncome":2334309.72565}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":8.61,"previousClose":8.49,"fiftyTwoWeekHigh":8.9,"fiftyTwoWeekLow":5.66,"fiftyTwoWeekRange":"5.66 - 8.9","fiftyDayAverage":7.24,"twoHundredDayAverage":6.37,"beta":0.04,"enterpriseValue":570110969.8705344,"forwardPE":31.9,"priceToBook":1.11,"priceToSales":1.88,"enterpriseToRevenue":1.74,"enterpriseToEbitda":15.84,"pegRatio":0,"ebitda":36002154.37,"ebitdaMargin":11,"freeCashflow":14857447.774574999,"operatingCashflow":50255072.04235,"totalDebt":56780644.71905,"debtToEquity":10.2,"currentRatio":2.39,"returnOnAssets":-0.1,"returnOnEquity":-0.7,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":7,"targetMeanPrice":8.77,"targetHighPrice":12,"targetLowPrice":6.15,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":47,"institutionHeldPercent":20.2,"sharesOutstanding":98251670,"floatShares":60135492,"sharesShort":1912154,"shortRatio":32.27,"shortPercentOfFloat":1.9,"epsTrailing":0.06,"epsForward":0.27,"revenuePerShare":4.52,"bookValue":7.74,"officers":[{"age":56,"name":"Mr. Jonathan Ross Goodman B.A., L.L.B., M.B.A.","title":"Executive Chairman"},{"age":57,"name":"Ms. Samira  Sakhia BCom, CA, CPA, MBA","title":"President, CEO & Director"},{"age":null,"name":"Mr. Arvind  Utchanah","title":"Chief Financial Officer"},{"age":null,"name":"Mr. Leopoldo  Bosano","title":"Vice-President of Manufacturing & Operations"},{"age":null,"name":"Ms. Susan Caroline Emblem","title":"Global Vice President of Human Resources"},{"age":null,"name":"Ms. Amal  Khouri B.Sc., M.B.A.","title":"Chief Business Officer"},{"age":null,"name":"Ms. Christine  Poulin","title":"General Manager of Canada"},{"age":null,"name":"Ms. Monica  Percario","title":"Global Vice President of Regulatory & Quality"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.knighttx.com","phone":"514-484-4483"}}